Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
18 févr. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
16 févr. 2021 08h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
09 févr. 2021 23h25 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
03 févr. 2021 07h55 HE
|
Enlivex Therapeutics Ltd
Phase II (16 patients treated, 9/16 (56%) with severe illness, 7/16 (44%) with critical illness, follow-up period of 28 days post-AllocetraTM treatment) 0/16 (0%) mortality on day-28 ...
Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
11 janv. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
21 déc. 2020 08h00 HE
|
Enlivex Therapeutics Ltd
– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and...
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
07 déc. 2020 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the China National...
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
03 déc. 2020 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of an...